Examples of 'vemurafenib' in a sentence
Meaning of "vemurafenib"
vemurafenib (noun) - A drug used in the treatment of certain types of cancer, particularly melanoma. It works by targeting specific genetic mutations in cancer cells
Show more definitions
- A drug for the treatment of late-stage melanoma.
How to use "vemurafenib" in a sentence
Basic
Advanced
vemurafenib
Interaction of vemurafenib with drug transport systems.
There is no specific antidote for overdose of vemurafenib.
Cotellic treatment and vemurafenib treatment should be interrupted.
Zelboraf contains the active substance vemurafenib.
The dose of vemurafenib may be reduced as clinically appropriate.
Two such compounds are dabrafenib and vemurafenib.
It is not known whether vemurafenib is excreted in human milk.
So vemurafenib increases the melanoma stem cell compartment.
Please refer to the vemurafenib SmPC.
Effects of vemurafenib on other medicinal products.
Carcinogenicity studies have not been conducted with vemurafenib.
Vemurafenib hydrochloride can preferably be provided in crystalline form.
Months for the placebo plus vemurafenib arm.
Therefore an effect of vemurafenib on the foetus can not be excluded.
Effect of other medicinal products on vemurafenib.
See also
Cotellic in combination with vemurafenib in patients with brain metastases.
Such chemotherapeutic agents include vemurafenib.
The possible effect of vemurafenib on other transporters is currently unknown.
Accumulation occurs upon multiple twice daily dosing of vemurafenib.
Vemurafenib causes programmed cell death in melanoma cell lines.
Patients were either naive to vemurafenib or had disease progression on vemurafenib.
Concurrent administration with vemurafenib.
It is currently unknown whether vemurafenib is a substrate also to other transport proteins.
Cotellic is used in combination with another medicine called vemurafenib.
The effect of food on steady state vemurafenib exposure is currently unknown.
Zelboraf is a medicine that contains the active substance vemurafenib.
The safety of vemurafenib in children and adolescents has not been established.
There are no data regarding the use of vemurafenib in pregnant women.
Vemurafenib is packaged in bottles.
No cases of overdose have been observed with vemurafenib in clinical trials.
Vemurafenib has minor influence on the ability to drive and use machines.
The active substance is vemurafenib.
Vemurafenib should be used with caution when given concomitantly or sequentially with radiation treatment.
Cases of cuSCC have been reported in patients treated with vemurafenib.
In a particularly preferred embodiment amorphous vemurafenib hydrochloride does not contain crystalline vemurafenib hydrochloride at all.
Some people lose their appetite while taking vemurafenib.
The amounts refer to the vemurafenib salt but not to the amounts of free base.
Effects of concomitant medicines on vemurafenib.
Some people treated with vemurafenib develop new skin cancers called squamous cell carcinomas.
Zelboraf is an anticancer medicine that contains the active substance vemurafenib.
Vemurafenib dosing can be continued when Cotellic treatment is modified.
No studies have been conducted to investigate the pharmacokinetics of vemurafenib in paediatric patients.
The effects of vemurafenib on medicinal products that are substrates of BCRP are unknown.
Caution should be used when ipilimumab is administered following prior vemurafenib.
Cotellic in combination with vemurafenib in patients who have progressed on a BRAF inhibitor.
All patients should be advised to avoid sun exposure while taking vemurafenib.
Vemurafenib dosing can be continued when Cotellic treatment is modified if clinically indicated.
Cardiovascular safety of cobimetinib in combination with vemurafenib has not been evaluated in vivo.
Patients with resistance had favorable clinical responses when chloroquine was added to vemurafenib.
Vemurafenib should not be used in patients with wild type BRAF malignant melanoma.
